uniQure (NASDAQ:QURE) Sees Strong Trading Volume – Still a Buy?

uniQure (NASDAQ:QURE) saw unusually-strong trading volume on Wednesday . Approximately 681,525 shares were traded during mid-day trading, a decline of 27% from the previous session’s volume of 930,653 shares.The stock last traded at $16.08 and had previously closed at $17.64.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. The Goldman Sachs Group raised their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Cantor Fitzgerald lifted their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Mizuho boosted their price target on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Finally, Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $33.88.

uniQure Trading Down 7.9 %

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s fifty day moving average is $10.83 and its 200-day moving average is $7.85. The stock has a market capitalization of $791.59 million, a PE ratio of -3.27 and a beta of 0.41.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. As a group, analysts anticipate that uniQure will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. bought a new stake in shares of uniQure in the third quarter worth $7,360,000. Geode Capital Management LLC lifted its position in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in uniQure in the third quarter worth about $283,000. Quarry LP acquired a new stake in uniQure during the third quarter valued at approximately $58,000. Finally, RTW Investments LP bought a new position in uniQure during the 3rd quarter worth approximately $49,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.